Current Clinical Trials
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
Henry Tsai, MD- for people 25 Years and up (full criteria)
- Rancho Mirage, CA
- study started January 2023
- Henry Tsai, MD
- Currently not accepting new patients
Description
Summary
This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.Official Title
A221805-Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III StudyDetailed Description
Keywords
Stage II Colorectal Cancer AJCC v8Eligibility
for people 25 Years and up
Clinical Study Details
- Currently not accepting new patients
- study started January 2023
- Interventional
- August 28, 2024